<?xml version='1.0' encoding='utf-8'?>
<document id="31174438"><sentence text="Development of an intravaginal ring delivering simultaneously anastrozole and levonorgestrel: a pharmacokinetic perspective."><entity charOffset="62-73" id="DDI-PubMed.31174438.s1.e0" text="anastrozole" /><entity charOffset="78-92" id="DDI-PubMed.31174438.s1.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.31174438.s1.e0" e2="DDI-PubMed.31174438.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31174438.s1.e0" e2="DDI-PubMed.31174438.s1.e1" /></sentence><sentence text="Intravaginal rings (IVRs) are an option for continuous administration of drugs in women" /><sentence text=" As an attractive approach for the treatment of endometriosis-associated pelvic pain, IVRs delivering a combination of the aromatase inhibitor anastrozole (ATZ) and the progestin levonorgestrel (LNG) have been developed"><entity charOffset="143-154" id="DDI-PubMed.31174438.s3.e0" text="anastrozole" /><entity charOffset="156-159" id="DDI-PubMed.31174438.s3.e1" text="ATZ" /><entity charOffset="169-193" id="DDI-PubMed.31174438.s3.e2" text="progestin levonorgestrel" /><entity charOffset="195-198" id="DDI-PubMed.31174438.s3.e3" text="LNG" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e0" e2="DDI-PubMed.31174438.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e0" e2="DDI-PubMed.31174438.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e0" e2="DDI-PubMed.31174438.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e0" e2="DDI-PubMed.31174438.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e1" e2="DDI-PubMed.31174438.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e1" e2="DDI-PubMed.31174438.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e1" e2="DDI-PubMed.31174438.s3.e3" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e2" e2="DDI-PubMed.31174438.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31174438.s3.e2" e2="DDI-PubMed.31174438.s3.e3" /></sentence><sentence text=" This article describes the developmental pharmacokinetic (PK) aspects covering the characterization of in vitro release, preclinical IVR PK investigations in monkeys, and clinical PK considerations" /><sentence text=" An IVR for ATZ has been developed and investigated in healthy menstruating female cynomolgus monkeys showing effective in vivo release"><entity charOffset="12-14" id="DDI-PubMed.31174438.s5.e0" text="ATZ" /></sentence><sentence text=" PK data from the size-adapted IVR used in these animals can be translated into a human context as confirmed in human studies where predefined exposure levels of ATZ were reached"><entity charOffset="162-164" id="DDI-PubMed.31174438.s6.e0" text="ATZ" /></sentence><sentence text=" As ATZ may cause harm to the fetus, use of effective contraception has to be assured in women of childbearing potential"><entity charOffset="4-6" id="DDI-PubMed.31174438.s7.e0" text="ATZ" /></sentence><sentence text=" Therefore, the IVR delivers a low dose of LNG as a contraceptive"><entity charOffset="43-45" id="DDI-PubMed.31174438.s8.e0" text="LNG" /></sentence><sentence text=" Although the daily dose differed strongly between both drugs (20 µg LNG/d to &gt;1 mg ATZ/d), simultaneous delivery of ATZ and LNG in vitro and in vivo was observed with a high correlation between the in vitro release and PK profiles"><entity charOffset="84-86" id="DDI-PubMed.31174438.s9.e0" text="ATZ" /><entity charOffset="117-119" id="DDI-PubMed.31174438.s9.e1" text="ATZ" /><entity charOffset="69-71" id="DDI-PubMed.31174438.s9.e2" text="LNG" /><entity charOffset="125-127" id="DDI-PubMed.31174438.s9.e3" text="LNG" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e2" e2="DDI-PubMed.31174438.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e2" e2="DDI-PubMed.31174438.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e2" e2="DDI-PubMed.31174438.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e2" e2="DDI-PubMed.31174438.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e0" e2="DDI-PubMed.31174438.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e0" e2="DDI-PubMed.31174438.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e0" e2="DDI-PubMed.31174438.s9.e3" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e1" e2="DDI-PubMed.31174438.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31174438.s9.e1" e2="DDI-PubMed.31174438.s9.e3" /></sentence><sentence text=" The PK characteristics successfully guided the design of clinical studies investigating the drug-drug interaction (DDI) potential" /><sentence text=" No relevant DDI between both the investigated or other vaginally administered drugs were identified" /><sentence text="" /></document>